Holland O B, Fairchild C, Gomez-Sanchez C E
J Clin Pharmacol. 1981 Apr;21(4):133-9. doi: 10.1002/j.1552-4604.1981.tb05690.x.
Patients with mild to moderate essential hypertension were treated with guanabenz plus placebo (26 patients) or guanabenz plus hydrochlorothiazide (26 patients) for one year. Ambulatory plasma renin activity was determined during placebo treatment, after four weeks and one year of treatment with the study drugs, and one month after discontinuation of guanabenz while continuing the same hydrochlorothiazide dosage. Treatment with guanabenz plus hydrochlorothiazide proved more satisfactory than treatment with guanabenz plus placebo in that fewer patients were treatment failures, a smaller dosage of guanabenz was required, better control of supine blood pressure was achieved, and no increase in guanabenz dosage was needed to maintain chronic blood pressure control. Drowsiness, dry mouth, and dizziness were the side effects noted most commonly. Plasma renin activity was not significantly suppressed by chronic guanabenz therapy. Thus, guanabenz is an effective new antihypertensive that provides optimal blood pressure control when used with a diuretic.
轻度至中度原发性高血压患者接受了胍那苄加安慰剂(26例患者)或胍那苄加氢氯噻嗪(26例患者)治疗,为期一年。在安慰剂治疗期间、使用研究药物治疗四周和一年后以及停用胍那苄而继续使用相同剂量氢氯噻嗪一个月后,测定动态血浆肾素活性。结果表明,胍那苄加氢氯噻嗪治疗比胍那苄加安慰剂治疗更令人满意,因为治疗失败的患者更少,所需的胍那苄剂量更小,仰卧位血压得到更好的控制,并且维持慢性血压控制无需增加胍那苄剂量。嗜睡、口干和头晕是最常出现的副作用。长期使用胍那苄治疗并未显著抑制血浆肾素活性。因此,胍那苄是一种有效的新型抗高血压药物,与利尿剂合用时可实现最佳血压控制。